News/ News/ R&D Gilead snaps up MiroBio and its checkpoint agonists for $405m Phil Taylor AnaptysBio, Eli Lilly, Gilead Sciences, Immunology and inflammation, M&A, MiroBio 0 Comment Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a Share X Gilead snaps up MiroBio and its checkpoint agonists for $405m https://pharmaphorum.com/news/gilead-snaps-up-mirobio-and-its-checkpoint-agonists-for-405m/